Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. According to ClinicalTrials.gov, there are over 1,360 clinical trials evaluating the use of cord blood and tissue-derived cells. These studies typically leverage unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). [Read more…]
8th Perinatal Stem Cell Society Congress/Workshop Coming Soon
The 8th Perinatal Stem Cell Society Congress/Workshop is taking place November 3, 2022, at the Westin Beach Resort in Fort Lauderdale, FL.
$599 Early Bird Ticket Sales Close Oct. 15th
After Oct. 15th the price is $899
Please register here
As a patient advocate, my aim is to create affordable access to safe stem cell and biologic therapies in the United States. There is an opportunity to work with FDA at this time to make substantial and long-lasting changes to the IND pathways. I have called this one-day workshop so that the industry can come together, not to challenge the FDA, but to work with FDA to find solutions that will enable access to life changing therapies for patients in the U.S. [Read more…]
denovoMATRIX Launches Cell Therapy Grade Consumables
DRESDEN, Germany, September. 19, 2022 /BioInformant/ — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, announced the launch of its animal component-free product lines at cell therapy grade (CTG). The new product lines will include documentation and traceability information for compliance with industry regulatory standards, designed for the stem cell therapy manufacturing market.
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma
LA JOLLA, CALIF (August 2, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a phase 1 physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (NeuroNova), a cutting-edge therapeutic candidate comprising tumor-tropic neural stem cells delivering an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma (Calidi’s NNV-2 program). [Read more…]
Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO
Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.
In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 60
- Next Page »